For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,431,482 | 2,766,269* | 1,056,560 | 1,242,340 |
| Research and development | 3,543,723 | 4,726,130.5* | 2,196,828 | 1,167,045 |
| Total operating expenses | 4,975,205 | 7,492,399.5 | 3,253,388 | 2,409,385 |
| Loss from operations | -4,975,205 | -7,492,399.5* | -3,253,388 | -2,409,385 |
| Other expense | - | 640* | - | - |
| Interest income | 44,270 | 38,417* | 37,023 | 38,609 |
| Interest expense | 6,111 | 5,778.5* | 2,116 | 4,185 |
| Total other income (expense) | 38,159 | 31,998.5* | 34,907 | 34,424 |
| Net loss | -4,937,046 | -7,460,401 | -3,218,481 | -2,374,961 |
| Basic EPS | -7.3 | -16.827 | -5.76 | -6.42 |
| Diluted EPS | -7.3 | -16.827 | -5.76 | -6.42 |
| Basic Average Shares | 676,172 | 443,369* | 558,868 | 370,127 |
| Diluted Average Shares | 676,172 | 443,369* | 558,868 | 370,127 |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)